None of the estimates for this biotechnology stock were revised over the past 30 days. However, its Zacks Consensus Estimate moved higher over the past few weeks/months, suggesting that more solid trading could be ahead for Protalix. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Protalix BioTherapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Some better-ranked stocks in the broader health care sector include Fibrocell Science, Inc. (FCSC), Emergent BioSolutions, Inc. (EBS) and Epizyme, Inc. (EPZM), each carrying a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment